Claudin 18.2
2 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A Phase I/II Study of FG-M108 Plus FG-B901 in Advanced CLDN18.2-Positive Solid Tumors (NCT07704866) | FutureGen Biopharmaceutical (Beijing) Co., Ltd | 2026-07-30 |
| Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody (NCT05994001) | Shanghai Zhongshan Hospital | 2023-08-01 |
Track Claudin 18.2 automatically
Every clearance here is in the API, with alerts when new ones post.